53292-89-0

Basic information

• Product Name: BOC-1,4-TRANS-ACHC-OH
• Synonyms: RARECHEM AR PA 0013;TRANS-4-TERT-BUTOXYCARBONYLAMINOCYCLOHEXANECARBOXYLIC ACID;TRANS-4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID;TRANS-1-(T-BUTYLOXYCARBONYLAMINO)CYCLOHEXYL-4-CARBOXYLIC ACID;TRANS-1-(TERT-BUTYLOXYCARBONYL-AMINO)-CYCLOHEXYL-4-CARBOXYLIC ACID;BOC-1,4-TRANS-ACHC-OH;BOC-TRANS-1,4-AMINOCYCLOHEXANE CARBOXYLIC ACID;BOC-TRANS-4-AMINOCYCLOHEXANE-1-CARBOXYLIC ACID
• CAS NO: 53292-89-0
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• Product Categories: Alicyclic Amino Acids;Peptide Synthesis;Unnatural Amino Acid Derivatives
• Mol File: 53292-89-0.mol
• Article Data: 11

Chemical Properties

• Melting Point: 181.0 to 185.0 °C
• Boiling Point: 396.7 °C at 760 mmHg
• Flash Point: 193.7 °C
• Appearance: White/Powder
• Density: 1.13 g/cm³
• Vapor Pressure: 2.12E-07mmHg at 25°C
• Refractive Index: 1.493
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Chloroform, Methanol (Slightly)
• PKA: 4.76±0.10(Predicted)
• BRN: 7641071
• CAS DataBase Reference: BOC-1,4-TRANS-ACHC-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-1,4-TRANS-ACHC-OH(53292-89-0)
• EPA Substance Registry System: BOC-1,4-TRANS-ACHC-OH(53292-89-0)

Safety Data

• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 53292-89-0(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Uses

Boc-trans-4-aminocyclohexanecarboxylic acid is a reagent to synthesize N-myristoyltransferase and CD38 inhibitors.

InChI:InChI=1/C12H21NO4/c1-12(2,3)17-11(16)13-9-6-4-8(5-7-9)10(14)15/h8-9H,4-7H2,1-3H3,(H,13,16)(H,14,15)/t8-,9-

Upstream product

• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 38446-95-6 4-oxocyclohexanecarboxylic acid tert-butyl ester 
• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 881657-40-5 tert-butyl ((3R,6S)-6-formyltetrahydro-2H-pyran-3-yl)carbamate 
• 603130-12-7 1,5-anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4-trideoxy-D-erythro-hexitol 
• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 150-13-0 4-amino-benzoic acid 
• 1776-53-0 trans-4-aminocyclohexanecarboxylic acid 

Downstream Products

• 944404-27-7 [trans-4-(4-isopropyl-piperazine-1-carbonyl)-cyclohexyl]-carbamic acid tert-butyl ester 
• 239074-29-4 trans (4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 1032451-72-1 (4-dimethylcarbamoyl-cyclohexyl)-carbamic acid tert-butyl ester 
• 757171-98-5 1-(trans-4-tert-butoxycarbonylaminocyclohexane-1-ylcarbonyl)-4-(5-chloro-2H-benzopyran-3-sulfonyl)piperazine 
• 216957-35-6 ethyl 1-(trans-4-tert-butoxycarbonylaminocyclohexane-1-ylcarbonyl)-4-(6-chloronaphthalene-2-sulfonyl)-2-piperazinecarboxylate 
• 216957-26-5 1-(trans-4-tert-butoxycarbonylaminocyclohexane-1-ylcarbonyl)-4-(6-chloronaphthalene-2-sulfonyl)piperazine 
• 878395-72-3 4-amino-cyclohexanecarboxylic acid [2-(cyclopentanecarbonyl-amino)-benzothiazol-6-yl]-amide 
• 400899-17-4 methanesulfonic acid 5-[4-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl]-pentyl ester 
• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 400899-16-3 [4-(5-hydroxy-pentyl)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 400899-10-7 3-[4-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl]-propionic acid ethyl ester 
• 400899-11-8 [4-(3-hydroxy-propyl)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 400899-12-9 methyl-[4-(3-oxo-propyl)-cyclohexyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors

In this study, a series of novel hydroxyamidine derivatives were identified as potent and selective IDO1 inhibitors by structure-based drug design. Among them, compounds 13-15 and 18 exhibited favorable enzymatic and cellular activities. Compound 18 showed improved bioavailability in mouse, rat, and dog (F% = 44%, 58.8%, 102.1%, respectively). With reasonable in vivo pharmacokinetic properties, compound 18 was further evaluated in a transgenic MC38 xenograft mouse model. The combination of compound 18 with PD-1 monoclonal antibody showed a synergistic antitumor effect. These data indicated that compound 18 as a potential cancer immunotherapy agent should warrant further investigation.

BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF

The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.

Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization

Small molecule stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes. Although chemical inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replicat